Camber Capital Management LP - Q1 2022 holdings

$2.76 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 100.0% .

 Value Shares↓ Weighting
INNV ExitINNOVAGE HLDG CORP$0-350,000
-100.0%
-0.06%
TBPH ExitTHERAVANCE BIOPHARMA INC$0-500,000
-100.0%
-0.19%
AVRO ExitAVROBIO INC$0-1,633,333
-100.0%
-0.22%
ALKS ExitALKERMES PLC$0-1,300,000
-100.0%
-1.04%
IRWD ExitIRONWOOD PHARMACEUTICALS INC$0-3,000,000
-100.0%
-1.20%
BIIB ExitBIOGEN INC$0-250,000
-100.0%
-2.06%
SNY ExitSANOFIcall$0-1,500,000
-100.0%
-2.58%
NVS ExitNOVARTIS AGcall$0-1,000,000
-100.0%
-3.01%
VRTX ExitVERTEX PHARMACEUTICALS INC$0-450,000
-100.0%
-3.40%
MRK ExitMERCK & CO INCcall$0-2,000,000
-100.0%
-5.27%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-05-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
TEVA PHARMACEUTICALS INDS LTD34Q3 20239.7%
BROOKDALE SR LIVING INC32Q3 20235.0%
PERRIGO CO PLC29Q3 20237.1%
TENET HEALTHCARE CORP28Q3 20238.5%
NEKTAR THERAPEUTICS28Q1 20229.8%
UNIVERSAL HLTH SVCS INC25Q3 20239.9%
MYRIAD GENETICS INC24Q3 20235.0%
SAREPTA THERAPEUTICS INC23Q3 20236.0%
MYLAN NV21Q3 202010.1%
AMAG PHARMACEUTICALS INC21Q3 20204.0%

View Camber Capital Management LP's complete holdings history.

Latest significant ownerships (13-D/G)

View Camber Capital Management LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
13F-HR2023-11-14
SC 13G2023-10-30
13F-HR2023-08-14

View Camber Capital Management LP's complete filings history.

Compare quarters

Export Camber Capital Management LP's holdings